Tuesday, July 12, 2011

Life Sciences: The Rodney Dangerfield of Venture Capital

Life Sciences: The Rodney Dangerfield of Venture Capital July 11, 2011

Note to Readers: This blog post was co-written by Bruce Booth and Bijan Salehizadeh, who co-authored an article in the July 2011 issue of Nature Biotechnology, detailing the differences in returns between Life Sciences and Tech investing.

Most venture capitalists think that Tech investing has been what makes the best returns – which is why they’re pouring money into Facebook, LinkedIn, Twitter, and the like. They may be right now and in the future, but at least over the past decade, they’ve been wrong: in the 2000′s, venture investing in the Life Sciences has outperformed venture investing in Tech.  Continue

No comments:

Post a Comment